UA90253C2 - Нетаблетированные жевательные дозировочные формы для индивидуального введения - Google Patents

Нетаблетированные жевательные дозировочные формы для индивидуального введения

Info

Publication number
UA90253C2
UA90253C2 UAA200606335A UAA200606335A UA90253C2 UA 90253 C2 UA90253 C2 UA 90253C2 UA A200606335 A UAA200606335 A UA A200606335A UA A200606335 A UAA200606335 A UA A200606335A UA 90253 C2 UA90253 C2 UA 90253C2
Authority
UA
Ukraine
Prior art keywords
tabletted
composition
water
administration forms
dosed administration
Prior art date
Application number
UAA200606335A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Видаль Хосе Луис Фабрегас
Карбонелл Антони Массо
Гонсалес Нуриа Гарсиа
Колл Пере Гуиро
Original Assignee
Лабораториос Алмиралл, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90253(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лабораториос Алмиралл, С.А. filed Critical Лабораториос Алмиралл, С.А.
Publication of UA90253C2 publication Critical patent/UA90253C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200606335A 2003-11-10 2004-11-09 Нетаблетированные жевательные дозировочные формы для индивидуального введения UA90253C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
UA90253C2 true UA90253C2 (ru) 2010-04-26

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200606335A UA90253C2 (ru) 2003-11-10 2004-11-09 Нетаблетированные жевательные дозировочные формы для индивидуального введения

Country Status (25)

Country Link
US (1) US20070134318A1 (de)
EP (1) EP1682097B1 (de)
JP (1) JP4879021B2 (de)
KR (1) KR20060116821A (de)
CN (1) CN1878542A (de)
AR (1) AR048050A1 (de)
AT (1) ATE492270T1 (de)
AU (1) AU2004290517B2 (de)
BR (1) BRPI0416215A (de)
CA (1) CA2548615A1 (de)
CO (1) CO5690531A2 (de)
DE (1) DE602004030706D1 (de)
EC (1) ECSP066553A (de)
ES (2) ES2235626B1 (de)
IL (1) IL175285A (de)
MY (1) MY143793A (de)
NO (1) NO20062723L (de)
NZ (1) NZ546375A (de)
PE (1) PE20050488A1 (de)
RU (1) RU2369379C2 (de)
TW (1) TW200526266A (de)
UA (1) UA90253C2 (de)
UY (1) UY28586A1 (de)
WO (2) WO2005048975A1 (de)
ZA (1) ZA200602416B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
JP5269894B2 (ja) * 2007-06-27 2013-08-21 ハンミ ファーム. シーオー., エルティーディー. 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010013242A1 (en) 2008-07-29 2010-02-04 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (de) * 2009-04-03 2012-06-27 Hexal AG Oraler Film mit 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-chinolin-2-on-Base oder Salze oder Hydrate davon
NZ597319A (en) 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration

Also Published As

Publication number Publication date
AU2004290517A1 (en) 2005-06-02
ECSP066553A (es) 2006-12-20
NZ546375A (en) 2009-11-27
WO2005048974A3 (en) 2006-02-23
TW200526266A (en) 2005-08-16
ES2358332T3 (es) 2011-05-09
IL175285A (en) 2011-04-28
ZA200602416B (en) 2009-06-24
US20070134318A1 (en) 2007-06-14
WO2005048975A1 (en) 2005-06-02
ES2235626B1 (es) 2006-11-01
MY143793A (en) 2011-07-15
BRPI0416215A (pt) 2006-12-26
JP2007510690A (ja) 2007-04-26
ATE492270T1 (de) 2011-01-15
NO20062723L (no) 2006-06-12
AU2004290517B2 (en) 2010-05-27
CA2548615A1 (en) 2005-06-02
JP4879021B2 (ja) 2012-02-15
RU2369379C2 (ru) 2009-10-10
PE20050488A1 (es) 2005-08-24
WO2005048974A2 (en) 2005-06-02
EP1682097A2 (de) 2006-07-26
RU2006120087A (ru) 2007-12-27
CO5690531A2 (es) 2006-10-31
UY28586A1 (es) 2005-05-31
EP1682097B1 (de) 2010-12-22
CN1878542A (zh) 2006-12-13
IL175285A0 (en) 2006-09-05
ES2235626A1 (es) 2005-07-01
AR048050A1 (es) 2006-03-29
DE602004030706D1 (de) 2011-02-03
KR20060116821A (ko) 2006-11-15

Similar Documents

Publication Publication Date Title
UA90253C2 (ru) Нетаблетированные жевательные дозировочные формы для индивидуального введения
BR0011347A (pt) Preparações e formas de administração compreendendo um composto ativo de ácido instável
ID26221A (id) Komposisi-komposisi farmasi yang dapat dijadikan gel
ATE279209T1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
CA2082137A1 (en) Aliphatic esters as a solventless coating for pharmaceuticals
ES2185758T3 (es) Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables.
CA2456180A1 (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
DK1024795T3 (da) Formuleringer med reguleret frigivelse
CA2409828A1 (en) Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
TWI255720B (en) Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
JP2007510690A5 (de)
HRP20020154B1 (en) Pharmaceutical compositions for oral and topical administration
KR960021018A (ko) 약제학적 조성물
WO2003017761A1 (fr) Agents vivifiants en poudre pour plantes
CN103396696A (zh) 可生物降解的环保型脱漆剂
ATE345777T1 (de) Biologisch aktive zusammensetzung
JPS5750914A (en) Betamethasone external pharmaceutical
ES2155048T1 (es) Composicion biologicamente activa.
AU5880290A (en) Compositions
TH73462A (th) รูปยาสำหรับการให้ยาที่กำหนดขนาดยาไว้ในแต่ละหน่วยที่เคี้ยวได้และไม่ได้ทำให้เป็นยาเม็ด
TH48988A3 (th) สารผสมของเหลวเอเควียสที่ใช้ทำความสะอาด
TH24457C3 (th) สารผสมของเหลวเอเควียสที่ใช้ทำความสะอาด